UBS Lifts Gilead Price Target to $175 Citing Next-Gen HIV Data
UBS raised its price target on Gilead Sciences to $175 from $155 and kept a Buy rating, pointing to imminent Phase I data on six-month long-acting HIV treatment candidates as the catalyst. The bank views these data as the next major advance in Gilead's HIV pipeline and a potential lever to sustain revenue past Biktarvy's patent protection through 2…